Tonix (NASDAQ: TNXP) CFO adds 1,453 shares through 2025 employee stock plan

Rhea-AI Filing Summary

Tonix Pharmaceuticals Holding Corp. Chief Financial Officer Bradley Saenger reported a routine share acquisition through an employee stock plan. He obtained 1,453 shares of common stock at a price of $10.914 per share via the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.

Following this transaction, Saenger directly holds 2,154 shares of Tonix common stock. The transaction is coded as “J” (other acquisition or disposition), reflecting a compensation-related, plan-based purchase rather than an open-market trade, so it carries limited signaling value about his view of the stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SAENGER BRADLEY

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Other	Common Stock, $0.001 par value	1,453	$10.914	$16K

Holdings After Transaction: Common Stock, $0.001 par value — 2,154 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 1,453 shares Purchase price: $10.914 per share Shares owned after transaction: 2,154 shares +1 more

4 metrics

Shares acquired 1,453 shares Acquired through 2025 Employee Stock Purchase Plan

Purchase price $10.914 per share Price for ESPP-acquired common stock

Shares owned after transaction 2,154 shares Direct holdings following Form 4 transaction

Restructuring-designated shares 1,453 shares Classified as restructuringShares in transaction summary

Key Terms

Employee Stock Purchase Plan, Other acquisition or disposition, Common Stock, $0.001 par value

3 terms

Employee Stock Purchase Plan financial

"Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Other acquisition or disposition financial

"transaction_code_description": "Other acquisition or disposition""

Common Stock, $0.001 par value financial

"security_title": "Common Stock, $0.001 par value""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 09:06 AM Accepted by SEC EDGAR 07/09/2026 - 09:05 AM Learn about SEC filing dates

FAQ

What insider transaction did Tonix (TNXP) CFO Bradley Saenger report?

Tonix CFO Bradley Saenger reported acquiring shares through the company’s 2025 Employee Stock Purchase Plan. The Form 4 shows this as a routine, plan-based transaction rather than an open-market trade, providing transparency on his updated equity holdings in Tonix Pharmaceuticals.

How many Tonix (TNXP) shares did the CFO acquire and at what price?

Bradley Saenger acquired 1,453 shares of Tonix common stock at $10.914 per share. These shares were obtained through the 2025 Employee Stock Purchase Plan, reflecting compensation-related participation rather than a discretionary open-market purchase of Tonix shares.

How many Tonix (TNXP) shares does the CFO hold after this Form 4 transaction?

After the reported transaction, Tonix CFO Bradley Saenger directly holds 2,154 shares of common stock. This total reflects his position following the acquisition of 1,453 shares through the 2025 Employee Stock Purchase Plan disclosed in the Form 4 filing.

What does transaction code J mean in the Tonix (TNXP) Form 4 filing?

Transaction code J denotes an “other acquisition or disposition” of securities. In this Tonix Form 4, it represents shares acquired by CFO Bradley Saenger through the 2025 Employee Stock Purchase Plan, rather than a standard open-market buy or sell transaction.

Was the Tonix (TNXP) CFO’s share acquisition an open-market purchase?

No, the Tonix CFO’s acquisition was not an open-market purchase. The footnote states the 1,453 shares were acquired through the 2025 Employee Stock Purchase Plan, indicating a compensation-related, plan-based transaction instead of a discretionary market trade in Tonix shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAENGER BRADLEY

(Last) (First) (Middle)

C/O TONIX PHARMACEUTICALS HOLDING CORP.

200 CONNELL DRIVE, SUITE 3100

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tonix Pharmaceuticals Holding Corp. [ TNXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.001 par value	06/30/2026		J(1)	V	1,453	A	$10.914	2,154	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.

	/s/ Bradley Saenger	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)